| Market Cap | 111.68M | P/E | - | EPS this Y | 40.50% | Ern Qtrly Grth | - |
| Income | -49.76M | Forward P/E | 70.00 | EPS next Y | 83.10% | 50D Avg Chg | -18.00% |
| Sales | 23.23M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -52.00% |
| Dividend | N/A | Price/Book | 0.49 | EPS next 5Y | - | 52W High Chg | -84.00% |
| Recommedations | 2.00 | Quick Ratio | 2.03 | Shares Outstanding | 10.64M | 52W Low Chg | 7.00% |
| Insider Own | 21.40% | ROA | -10.90% | Shares Float | 8.20M | Beta | -0.16 |
| Inst Own | 13.94% | ROE | -23.71% | Shares Shorted/Prior | 6.94K/27.51K | Price | 0.70 |
| Gross Margin | 48.02% | Profit Margin | -262.11% | Avg. Volume | 151,390 | Target Price | 9.00 |
| Oper. Margin | -142.81% | Earnings Date | - | Volume | 232,840 | Change | 1.45% |
Prenetics Global Limited, a health sciences company, focuses on advancing consumer and clinical health. The company's consumer initiatives is led by IM8, a new health and wellness brand. Its prevention arm, CircleDNA, uses next-generation sequencing (NGS) technology to offer comprehensive consumer DNA test. It also develops and commercializes Insighta, a multi-cancer early detection technology. In addition, the company offers a range of genomic profiling panels tailored for requirements and clinician needs, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests. Further, the company offers ACTLiquid Pro, a sequencing based liquid biopsy assay for pan-solid tumors; ACTMonitor, which provides real time monitoring of drug resistance, treatment response, and cancer recurrence; and ACT Risk, which manages the cancer risk. It operates in Taiwan, Hong Kong, the United Kingdom, and internationally. The company was founded in 2014 and is based in Quarry Bay, Hong Kong and has a presence in the United States.
| Cantor Fitzgerald | Overweight | Apr 4, 24 |